Association Between Il17a Polymorphism And Clinicopathological Parameters In Egyptian Multiple Myeloma Patients

Context Multiple myeloma (MM) is a B-cell lymphoproliferative disorder in which the bone marrow (BM) microenvironment plays a key role in pathogenesis. T-helper 17 cells present within the BM microenvironment and secrete the pro-inflammatory cytokine interleukin-17 (IL-17). Single nucleotide polymorphisms (SNPs) in IL-17 (IL17A) are found to be involved in the pathogenesis of many cancers and autoimmune diseases. Objective To investigate the role of IL17A SNPs in MM pathogenesis and their impact on clinical features of MM. Design A prospective study conducted on 77 MM patients and healthy controls of matched age and gender. Setting The study was carried out in the Oncology Center, Mansoura University. Patients Seventy-seven patients with MM (female; 46.8%, male; 53.2%) with mean age of 54.6 years. Interventions We obtained genomic DNA from 77 patients with MM and healthy controls and detected IL17A-197 G/A (rs2275913) genotypes using the polymerase chain reaction-restriction fragment length polymorphism method. Main Outcome Measures The significance of IL17A polymorphism in relation to clinical data, laboratory data, and survival outcome. Results The IL17A polymorphism was not involved in susceptibility to MM in the Egyptian population, and there was no statistically significant association with gender (p=0.14), hypercalcemia (p=0.28), hypoalbuminemia (p=0.49), renal impairment (p=0.13), elevated LDH (p =0.62), osteolytic bone lesions (p=0.26), pathological fracture (p=0.96), plasmacytoma (p=0.42), and ISS stage III (p=0.26). IL17A polymorphism showed no statistically significant differences in OS (p=0.83) of MM patients, while there was a statistically significant worse OS among patients with thrombocytopenia (p=0.006), renal impairment (p=0.047), and ISS stage III (p=0.02). Conclusion In this study, IL17A polymorphism was not associated with susceptibility to MM and did not influence its severity. In addition, OS survival in MM patients was not affected by IL17A polymorphism.